Kanamycin: Difference between revisions
No edit summary |
m (Protected "Kanamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
(No difference)
|
Revision as of 19:04, 27 September 2011
Error creating thumbnail: File missing | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral, intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | very low after oral delivery |
Metabolism | ? |
Elimination half-life | 2 hours 30 minutes |
Excretion | ? |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H36N4O11 |
Molar mass | 484.499 |
WikiDoc Resources for Kanamycin |
Articles |
---|
Most recent articles on Kanamycin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Kanamycin at Clinical Trials.gov Clinical Trials on Kanamycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Kanamycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Kanamycin Discussion groups on Kanamycin Directions to Hospitals Treating Kanamycin Risk calculators and risk factors for Kanamycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Kanamycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Kanamycin sulfate ® is an aminoglycoside antibiotic, available in both oral and intravenous forms, and used to treat a wide variety of infections. Kanamycin is isolated from Streptomyces kanamyceticus.
Pharmacology
Kanamycin works by affecting the 30S ribosomal subunit and causing a frameshift mutation or it prevents the translation of RNA. This means that instead of a codon CAT (for example in sequence CATG), a codon ATG is read by aminoacyl tRNA (aa-tRNA). Aminoacyl tRNA is consequently carrying a different amino acid, because the anticodon on the aa-tRNA is different. The protein needed cannot be synthesized: depending on the site and severity of the frame shift, either a completely different protein is synthesized, or a protein similar to the one needed is synthesized, but is folded incorrectly. A bacterium is destroyed because it cannot produce any of its proteins correctly.
Because of over-usage of antibiotics many bacteria have developed a resistance against kanamycin, and, consequently, it is not used much anymore.
Side effects
Common side effects include changes in hearing (either hearing loss or ringing in the ears), toxicity to kidneys, and allergic reactions to the drug.
Use in Research
Genes encoding kanamycin resistance are commonly used as selectable markers in molecular biology.
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents Template:AminoglycosideAntiBiotics Template:SIB de:Kanamycin th:กานามัยซิน
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Aminoglycoside antibiotics